Growth Metrics

Pfizer (PFE) Non-Current Debt (2016 - 2026)

Pfizer has reported Non-Current Debt over the past 18 years, most recently at $60.6 billion for Q1 2026.

  • Quarterly Non-Current Debt rose 5.08% to $60.6 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $60.6 billion through Mar 2026, up 5.08% year-over-year, with the annual reading at $61.6 billion for FY2025, 8.14% up from the prior year.
  • Non-Current Debt was $60.6 billion for Q1 2026 at Pfizer, down from $61.6 billion in the prior quarter.
  • Over five years, Non-Current Debt peaked at $61.6 billion in Q4 2025 and troughed at $31.7 billion in Q2 2023.
  • The 5-year median for Non-Current Debt is $57.5 billion (2024), against an average of $51.7 billion.
  • Year-over-year, Non-Current Debt dropped 11.08% in 2023 and then soared 93.37% in 2024.
  • A 5-year view of Non-Current Debt shows it stood at $32.9 billion in 2022, then soared by 87.14% to $61.5 billion in 2023, then dropped by 7.37% to $57.0 billion in 2024, then increased by 8.14% to $61.6 billion in 2025, then fell by 1.75% to $60.6 billion in 2026.
  • Per Business Quant, the three most recent readings for PFE's Non-Current Debt are $60.6 billion (Q1 2026), $61.6 billion (Q4 2025), and $57.4 billion (Q3 2025).